Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation

Détails

ID Serval
serval:BIB_9D8AA9C81546
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation
Périodique
Fertility and Sterility
Auteur⸱e⸱s
Hazout  A., de Ziegler  D., Cornel  C., Fernandez  H., Lelaidier  C., Frydman  R.
ISSN
0015-0282
Statut éditorial
Publié
Date de publication
03/1993
Peer-reviewed
Oui
Volume
59
Numéro
3
Pages
596-600
Notes
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial --- Old month value: Mar
Résumé
OBJECTIVE: To compare two treatment regimens associating a gonadotropin-releasing hormone agonist (GnRH-a) and human menopausal gonadotropin (hMG) for controlled ovarian hyperstimulation (COH). DESIGN: A prospective randomized trial. SETTING: The outpatient fertility clinic of a university tertiary care center, the Hopital A. Beclere, Clamart, France. PARTICIPANTS: One hundred eighty-two in vitro fertilization (IVF) candidates undergoing new or repeat IVF cycles at Hopital A. Beclere over a 4-month period. TREATMENT: Group 1 (7-day protocol): A short-acting preparation of GnRH-a (Tripteriline 0.1) was administered daily for 7 days, starting on cycle day 2. Ovarian stimulation with hMG was started on cycle day 4. Group 2 (long protocol): A timed release preparation of GnRH-a (Tripteriline 3.75 mg) was administered on cycle day 2. Ovarian stimulation with hMG was started after documented ovarian suppression. MAIN OUTCOME MEASURES: Response to COH, pregnancy rate (PR), tolerance. RESULTS: In the 7-day protocol, the amount of hMG required was markedly lower at 24 +/- 7 than in the long protocol group requiring 42.5 +/- 9.75 vials (75 IU) (mean +/- SD). No elevation of plasma LH occurred in either group. The number of oocytes retrieved was 7.3 +/- 1 and 10.7 +/- 1.2 (mean +/- SD) in the 7-day and long protocols, respectively. Yet, the number of embryos obtained and the PRs were similar in the two treatment groups. CONCLUSIONS: We observed that in COH, GnRH-a treatment could be interrupted safely several days before human chorionic gonadotropin administration without risking a premature increase of plasma luteinizing hormone. Moreover, the number of embryos available for fresh transfer and the ongoing PRs were similar in the new 7-day and in the classic long GnRH-a/hMG protocols, despite the smaller number of oocytes suggesting a greater efficiency of the 7-day protocol. The peak estradiol level and the hMG requirement were also lower in the 7-day GnRH-a/hMG protocol.
Mots-clé
Adult Delayed-Action Preparations Embryo Transfer Female Fertilization in Vitro Humans Infertility, Female/drug therapy Luteinizing Hormone/blood Menotropins/administration & dosage/therapeutic use Ovary/*drug effects Prospective Studies Time Factors Triptorelin/*administration & dosage/therapeutic use
Pubmed
Web of science
Création de la notice
28/02/2008 11:37
Dernière modification de la notice
20/08/2019 15:03
Données d'usage